Stem cell therapy for COPD involves safety risks including vascular embolism, pulmonary distress, and potential tumor growth if cells proliferate incorrectly. While mesenchymal cells are generally well-tolerated, patients may experience transient fever, fatigue, or localized infection at the donor extraction site or IV injection point.
- Vascular risks: Intravenous delivery can cause cell clumping, leading to life-threatening pulmonary embolisms.
- Product quality: Contaminated or unapproved biologics pose high risks of severe bacterial infections.
- Respiratory impact: Poorly controlled infusions can block capillaries, triggering acute distress or worsening breathing.
- Immune reactions: Donor cells may cause rejection or require immunosuppressants, increasing vulnerability to infections.
Bookimed Expert Insight: Mexico clinics often bundle specialized regenerative treatments with comprehensive logistics to mitigate travel-related stress. For example, REHABILITA Regenerative Medicine includes VIP transfers and 5-star hotel stays. This level of service ensures patients remain in a controlled, low-stress environment during the critical 3-day window following infusion.
Patient Consensus: Patients frequently describe this therapy as a high-cost gamble. Many warn of transient worsening of breathing and chest tightness immediately after the procedure.